Richard Sipes
Addiction Medicine · Shreveport, LANPI 1528063252
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,000 of the $56,473 with a category attached, or 70.8%. Indivior Inc. accounts for 98.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $34,552 and has fallen 97.8% since, to $747 in 2025. Among addiction medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $294.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$55K
- Braeburn Inc.$472
- Gilead$239
- Johnson & Johnson$196
- Alpha Cognition USA, Inc.$56
- Teva Pharmaceuticals USA, Inc.$42
- plus $89 from 4 others
What the payments were for
- Speaking & faculty fees$40,00071%
- Travel & lodging$12,20622%
- Food & beverage$4,2468%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 165 | $55,380 |
| Braeburn Inc. | 13 | $472 |
| Gilead | 3 | $239 |
| Johnson & Johnson | 3 | $196 |
| Alpha Cognition USA, Inc. | 2 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Alkermes, Inc. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUBLOCADE$53,300
- BRIXADI$245
- INVEGA SUSTENNA$125
- Epclusa$125
How this compares
$56,473 in reported general payments places this provider in the 95th percentile of 28 addiction medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 103 | $9,642 |
| Buprenorphine Hcl | 123 | $6,615 |
| Fentanyl | 11 | $1,291 |
| Naloxone Hcl | 12 | $1,225 |
| Gabapentin | 18 | $595 |
| Trazodone Hcl | 28 | $378 |
| Hydroxyzine Pamoate | 23 | $275 |
| Paroxetine Hcl | 18 | $273 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $220 |
| Quetiapine Fumarate | 12 | $207 |
| Levothyroxine Sodium | 12 | $186 |
| Lorazepam | 14 | $146 |
| Clonazepam | 30 | $82 |
| Diazepam | 14 | $37 |
| Potassium Chloride | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl | $21 | $16,258226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 addiction medicine providers in Louisiana.
Other addiction medicine in Shreveport
- Kirit PatelShreveport$37K
- Philip IsherwoodShreveport$4K
- Cheryl SmithShreveport$166
- Susan JuliusBaton Rouge$255K
- Christina JonesSulphur$44K
- Alphonse RoyMetairie$23K
- Indira KailasMarrero$3K
- James ChivertonMetairie$2K
- Anthony PeperoneMandeville$2K
- Brandie SmithCovington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.